Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27802620 | 0.98 | ALDH1A1 (0.39) | ALDH1A1FFAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2466535 | 0.84 | FFAR1 (0.47) | ALDH1A1FFAR1CYP1A2MAPK1TSHR | |
| SCHEMBL30468202 | 0.84 | FFAR1 (0.47) | ALDH1A1FFAR1CYP1A2MAPK1TSHR | |
| SCHEMBL6364807 | 0.81 | CYP1A2 (0.46) | ALDH1A1CYP1A1CYP1A2CYP1B1TSHR | |
| SCHEMBL20912027 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL28016124 | 0.79 | FFAR1 (0.41) | ALDH1A1FFAR1CYP1A2MAPK1TAAR1 | |
| SCHEMBL2173149 | 0.79 | FFAR1 (0.41) | ALDH1A1FFAR1CYP1A2MAPK1TAAR1 | |
| SCHEMBL9948640 | 0.78 | KCNH2 (0.32) | ALDH1A1 | |
| SCHEMBL28401249 | 0.77 | FFAR1 (0.40) | ALDH1A1FFAR1MAPK1TAAR1CA1 | |
| SCHEMBL20089254 | 0.76 | FFAR1 (0.41) | ALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373900-A1 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2023-11-23 | — | — | US | disclosed |
| US-20230373900-A1 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2023-11-23 | — | — | US | disclosed |
| CN-110590722-B | Synthesis method of 2-trifluoromethyl benzofuran derivative | 温州大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-108463462-B | Benzodiazepines as bromodomain inhibitors | 催化剂治疗私人有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-110590722-A | Synthesis method of 2-trifluoromethyl benzofuran derivative | 温州大学 | 2019-12-20 | — | — | CN | disclosed |
| US-10167292-B2 | Benzodiazepines as bromodomain inhibitors | Catalyst Therapeutics Pty Ltd. (AU) | 2019-01-01 | — | — | US | disclosed |
| US-10167292-B2 | Benzodiazepines as bromodomain inhibitors | Catalyst Therapeutics Pty Ltd. (AU) | 2019-01-01 | — | — | US | disclosed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3331887-A1 | BENZODIAZEPINES AS BROMODOMAIN INHIBITORS | Catalyst Therapeutics Pty Ltd. (AU) | 2018-06-13 | — | — | EP | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | CRYSOPTIX KK | 2011-03-17 | — | — | US | disclosed |
| EP-2260036-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009109782-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2009-09-11 | — | — | WO | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | MCM3, CCNA2, CCNB2 | ALDH1A1 4124/4885FFAR1 4846/4885CYP1A1 1757/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885FFAR1 4028/4885CYP1A1 3730/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885FFAR1 4028/4885CYP1A1 3730/4885 |
| US-10167292-B2 | Benzodiazepines as bromodomain inhibitors | BRD1, BRD3, BRD2 | ALDH1A1 496/4885FFAR1 629/4885CYP1A1 112/4885 |
| US-20230373900-A1 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | DHPS, CYP11B2, PIN1 | ALDH1A1 1231/4885FFAR1 4793/4885CYP1A1 94/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | ALDH1A1 2525/4885FFAR1 4511/4885CYP1A1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.